$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Abstract

Fexofenadine HCl is non-sedating histamine H1 receptor antagonist that can be used for the treatment of seasonal allergic rhinitis. The objective of this study was to investigate whether the carriers of deformable liposomes can enhance the transepithelial permeability of fexofenadine HCl across the in vitro ALI human nasal monolayer model. Characterization of this model was achieved by bioelectric measurements and morphological studies. The passage 2 and 3 of cell monolayers exhibited the TEER value of $2852\;{\pm}\;482\;ohm\;{\times}\;cm^2$ on 11 days of seeding and maintained high TEER value for 5 days. The deformable liposome of fexofenadine HCl was prepared with phosphatidylcholine (PC) and cholic acid using extruder method. The mean particle size was about 200 nm and the maximum entrapment efficiency of 33.0% was obtained in the formulation of 1% PC and $100\;{\mu}g/ml$ fexofenadine HCl. The toxicity of the deformable liposome to human nasal monolayers was evaluated by MTT assay and TEER value change. MTT assay showed that it has no toxic effect on the nasal epithelial cells in 2-hour incubation when the PC concentration was below 1%. However, deformable liposome could not enhance the transepithelial permeability $(P_{app})$ and cellular uptake of fexofenadine HCl. In conclusion, the in vitro model could be used in nasal drug transport studies and evaluation of transepithelial permeability of formulations.

참고문헌 (19)

  1. C. Lippert, J. Ling, P. Brown, S. Burmaster, M. Eller, L. Cheng, R. Thompson and S. Weir, Mass balance and pharmacokinetics of MDLl6445A in healthy male volunteers, Pharm. Res., 12, S390 (1995). 
  2. S. Turker, E. Onur E. and Y. Ozer, Nasal route and drug delivery systems, Pharm. World Sci., 26, 137-42 (2004) 
  3. P. Arora, S. Sharma and S. Garg, Permeability issues in nasal drug delivery, Drug Discovery Today, 7, 967-975 (2002) 
  4. T. Kissel and U. Werner, Nasal delivery of peptides: an in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium, J. Con. Rel., 53, 195-203 (1998) 
  5. M.K. Lee, J.W. Yoo, H. Lin, D.D. Kim and H.J. Roh, Serially passaged human nasal epithelial cell monolayer for drug transport studies: Comparison between liquid-cover condition (LCC) and air-liquid interface (ALI) culture condition, submitted for publication in Int. J. Pharm 
  6. W.J. Irwin, A.K. Dwivedi, P.A. Holbrook and M. J. Dey, The effect of cyclodextrins on the stability of peptides in nasal enzymatic systems, Pharm. Res., 11, 1698-1703 (1994) 
  7. K.I. Hosoya, H. Kubo, H. Natsume, K. Sugibayashi and Y. Morimoto, Evaluation of enhancers to increase nasal absorption using Ussing chamber technique, BioI. Pharm. Bull., 17, 316-322 (1994) 
  8. F.W.H.M. Merkus, J.C. Verhoef, E. Marttin, S.G. Romeijn, P.H.M. van der Kuy, W.A.J.J. Hermens and N.G.M. Schipper, Cyclodextrins in nasal drug delivery, Adv. Drug Del. Rev., 36, 41-57 (1999) 
  9. K. Morimoto, H. Katsumata, T. Yabuta, K. Iwanaga, M. Kakemi, Y. Tabata and Y. Ikada, Design of gelatinmicrospheres for pulmonary, nasal and intramuscular administrations of salmon-calcitonin, Proceedings of the 26th international symposium on controlled release of bioactive materials, Controlled Release Society, pp. 307-308 (1999) 
  10. S.S. Davis and L. Illum, Absorption enhancers for nasal drug delivery, Clin. Pharm., 42, 1107-1128 (2003) 
  11. G. Cevc and G. Blume, Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force, Biochim. Biophys. Acta, 1104, 226-32 (1992) 
  12. G. Cevc, Deformable liposomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery, Crit. Rev. Ther. Drug Carrier Syst., 13, 257-388 (1996) 
  13. S.I. Simoes, C.M. Marques, M.E.M. Cruz, G. Cevc and M.B.E Martins, The effect of cholate on solubilisation and permeability of simple and protein-loaded phosphatidylcholine/sodium cholate mixed aggregates designed to mediate transdermal delivery of macromolecules, Eur. J. Pharm. Biopharm., 58, 509-519 (2004) 
  14. R.U. Agu, M. Jorissen, R. Kinget, N. Verbeke and P. Augustijns, Alternatives to in vivo nasal toxicological screening for nasally-administered drugs, S.T.P. Pharm. Sci., 12, 13-22 (2002) 
  15. J. D. Kilgour, S.A. Simpson, D.J. Alexander and C.J. Reed, A rat nasal epithelial model for predicting upper respiratory tract toxicity: in vivo-in vitro correlations, Toxicology, 145, 39-49 (2000) 
  16. R.G. Rengel, K Barisic, Z. Pavelic, T.Z. Grubisic, I. Cepelak and J.F Grcic, High efficiency entrapment of superoxide dismutase into mucoadhesive chitosan-coated liposomes, Eur. J. Pharm. Sci., 15, 441-448 (2002) 
  17. S. Prior, B. Gander, N. Blarer, H.P. Merkle, M.L. Subria, J.M. Irache and C. Gamazo, In vitro phagocytosis and monocytemacrophage activation with poly (lactide) and poly (lactide-coglycolide) microphere, Eur. J. Pharm. Sci., 15, 197-207 (2002) 
  18. N.R. Mathias, K.J. Kim, T.W. Robison and Y.H. Lee, Development and characterization of rabbit tracheal epithelial cell monolayer models for drug transport studies, Pharm. Res., 12, 1499-1505 (1995) 
  19. N. W. Shappell, Ergovaline toxicity on Caco-2 cells as assessed by MTT, alamarBlue, and DNA assays, In Vitro Cell Dev. Bioi. Anim., 39, 329-35 (2003) 

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일